➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Express Scripts
Dow
Colorcon
Johnson and Johnson

Last Updated: April 22, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MYOBLOC

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for MYOBLOC

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00125203 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed ALS Association Phase 2/Phase 3 2003-07-01 The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.
NCT00125203 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System Phase 2/Phase 3 2003-07-01 The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.
NCT00125203 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed University of Kansas Phase 2/Phase 3 2003-07-01 The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.
NCT00125203 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed The University of Texas Health Science Center at San Antonio Phase 2/Phase 3 2003-07-01 The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.
NCT00208091 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia Completed Solstice Neurosciences Phase 4 2003-04-01 This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences). Myobloc is a purified and diluted form of botulinum toxin used medically to relax unwanted muscle spasms and movements. The aim of the study is to determine the feasibility of quantifying change in performance following treatment.
NCT00208091 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia Completed Columbia University Phase 4 2003-04-01 This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences). Myobloc is a purified and diluted form of botulinum toxin used medically to relax unwanted muscle spasms and movements. The aim of the study is to determine the feasibility of quantifying change in performance following treatment.
NCT00238641 “DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?” Completed Elan Pharmaceuticals Phase 1/Phase 2 2002-01-01 In children with cerebral palsy, stiffness of the arm can develop early and delay or prevent the acquisition of normal hand skills. Improvement in functional use of the hand may therefore be dependent upon early treatment of upper extremity hypertonia. We propose to test a series of injections of Myobloc™ in a non-randomized one-way crossover pilot clinical trial and dose-finding study, with clinical assessments and blinded video evaluations. Ten children age 2-17 years with increased tone at the elbow or wrist will be expected to complete the study. A 1-month baseline evaluation period will be followed by an injection of low-dose Myobloc™ to affected muscle(s) of the arm according to standardized per-kilogram dosing with a maximum of 25U/kg in each affected arm. Three months later, a second injection of up to 50U/kg will be performed in each affected arm. Three months after the second dose, a third dose of up to 100U/kg will be performed in each affected arm. Neurological assessments will be performed at study entry, prior to each injection, and at 1 and 3 months following each injection. Routine physical therapy and non-study medications will be continued during the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MYOBLOC

Condition Name

Condition Name for MYOBLOC
Intervention Trials
Sialorrhea 3
Stroke 2
Cerebral Palsy 2
Low Back Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for MYOBLOC
Intervention Trials
Muscle Spasticity 4
Sialorrhea 3
Low Back Pain 2
Spinal Cord Injuries 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for MYOBLOC

Trials by Country

Trials by Country for MYOBLOC
Location Trials
United States 42
Russian Federation 4
Ukraine 2
Lebanon 1
Belarus 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for MYOBLOC
Location Trials
Maryland 3
California 3
New York 3
District of Columbia 3
Tennessee 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for MYOBLOC

Clinical Trial Phase

Clinical Trial Phase for MYOBLOC
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 2/Phase 3 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for MYOBLOC
Clinical Trial Phase Trials
Completed 6
Not yet recruiting 3
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MYOBLOC

Sponsor Name

Sponsor Name for MYOBLOC
Sponsor Trials
US WorldMeds LLC 3
Solstice Neurosciences 2
United States Department of Defense 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for MYOBLOC
Sponsor Trials
Other 10
Industry 7
U.S. Fed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Boehringer Ingelheim
Harvard Business School
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.